RE:Roche/Genentech in race for CAR-T therapy in solid tumorsDecember 06, 2022- Poseida Therapeutics, Inc. early stage product P-BCMA-ALLO1 is an allogeneic CAR-T product candidate, partnered with Roche, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma in Phase 1 development. product.
Early clinical (safety) results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 are being presented at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.
https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-early-data-from-phase-1-trials-of-p-muc1c-allo1-and-p-bcma-allo1-at-esmo-immuno-oncology-2022-annual-congress-301695191.html